Frequency and Risk Factors of Congestive Heart Failure in Dialysis Patients
NCT ID: NCT04441346
Last Updated: 2020-06-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
289 participants
OBSERVATIONAL
2020-06-30
2021-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
To assess the frequency of heart failure in patients with end-stage renal disease on regular dialysis.
To identify the risk factors of heart failure in patients with end-stage renal disease.
To assess the impact of duration of dialysis on heart failure and its prognosis
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Incidence of Infective Endocarditis in End Stage Renal Disease Patients on Hemodialysis by Transesophageal Echocardiography in Assuit University Hospital
NCT05692089
Predictors of Acute Kidney Injury in Patients With Acute Decompensated Heart Failure in Emergency
NCT06463964
Clinical Findings and Albuminuria as Predictors of Acute Kidney Injury in Patients With Acute Heart Failure
NCT06621862
Acute Renal Insufficiency (ARI) Rate and Predictive Score of ARI in Hospitalized Patients for Acute Coronary Syndrome With ST-segment Elevation Needing Urgent Coronarography
NCT04481126
Risk Assessment by Cardiovascular Biomarkers in Chronic Dialysis Patients
NCT02207153
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
CHF is an independent risk factor for early mortality in ESRD patients. More than half of all deaths among ESRD patients are due to cardiovascular disease (CVD). Cardiovascular changes secondary to renal dysfunction, including fluid overload, uremic cardiomyopathy, secondary hyperparathyroidism, anemia, altered lipid metabolism, and accumulation of gut microbiota-derived uremic toxins like trimethylamine N-oxidase (TMAO), contribute to the high risk for CVD in the ESRD population. Also, conventional hemodialysis (HD) itself poses myocardial stress and injury to the already compromised cardiovascular system in uremic patients.
The characteristics of cardiovascular dysfunction observed in dialysis patients are distinct from those noted in the general population. Although traditional cardiovascular risk factors in patients with end-stage renal disease (ESRD) are highly prevalent, they play only a partial role in the excessive cardiovascular morbidity and mortality of this population. The paradoxical association between several traditional risk factors, such as body mass index, blood pressure (BP) and serum cholesterol, and mortality have been previously reported.
In the ESRD population, Hemodialysis (HD) contributes itself to the development of CHF with sustained fluid overload a major cause of hypertension, heart failure, and mortality in patients with ESRD. We postulate that repeated myocardial micro-injury during maintenance hemodialysis may lead to irreversible cardiac dysfunction and subsequent heart failure and death in some patients.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
patients with recent hemodialysis(less than 6 month
Echocardiography
test that uses high frequency sound waves (ultrasound) to make pictures of your heart.
patients on hemodialysis more than 6 months and l
Echocardiography
test that uses high frequency sound waves (ultrasound) to make pictures of your heart.
patients on hemodialysis more than 5 years
Echocardiography
test that uses high frequency sound waves (ultrasound) to make pictures of your heart.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Echocardiography
test that uses high frequency sound waves (ultrasound) to make pictures of your heart.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patients discontinued therapy during the study period will be excluded.
* Patients with structural heart disease (congenital or valvular heart disease)
* Patients with obstructive or restrictive lung diseases.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assiut University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Esraa Galal
Resident Doctor, internal medicine department, principal investigator
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CHF in Dialysis patients
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.